Streetbeat News

Analyst Ratings

WWD

Barclays analyst David Strauss maintains an Equal-Weight rating on Woodward (NASDAQ:WWD) and raises the price target from $112 to $128.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 08, 2023 | 12:45 pm

USM

JP Morgan analyst Philip Cusick has upgraded United States Cellular (NYSE:USM) from Neutral to Overweight.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:45 pm

WBD

Barclays analyst Kannan Venkateshwar has maintained an Equal-Weight rating on Warner Bros. Discovery (NASDAQ:WBD) and raised the price target from $14 to $15.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 08, 2023 | 12:43 pm

INZY

Inozyme Pharma reported Q2 losses of $(0.35) per share, beating the analyst consensus estimate of $(0.43) by 18.6 percent. This represents a 7.89 percent increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:43 pm

TDC

Barclays analyst Raimo Lenschow maintains an Underweight rating on Teradata (NYSE:TDC) and has lowered the price target from $47 to $46.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 08, 2023 | 12:41 pm

PLTR

Wedbush analyst Daniel Ives has reiterated an 'Outperform' rating on Palantir Technologies (NYSE:PLTR) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:41 pm

KDNY

Wedbush analyst Laura Chico has downgraded Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Neutral and set a price target of $42.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:41 pm

ANAB

Wedbush analyst David Nierengarten has maintained a Neutral rating on AnaptysBio (NASDAQ:ANAB) and lowered the price target from $29 to $26.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:40 pm

KROS

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Keros Therapeutics (NASDAQ:KROS) and maintained a price target of $86.

Portfolio Pulse from richadhand@benzinga.com

August 08, 2023 | 12:37 pm

EXPD

Expeditors Intl (NASDAQ:EXPD) reported Q2 earnings of $1.30 per share, missing the analyst consensus estimate of $1.34 by 2.99%. This is a 42.73% decrease from the same period last year. The company also reported quarterly sales of $2.24 billion, missing the analyst consensus estimate of $2.88 billion by 22.20%. This is a 51.34% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 12:36 pm